Alzinova
- Company typePublic
- Founded2011
- HeadquartersGothenburg, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Alzinova firmographics
Firmographics- Name
- Alzinova
- Legal name
- Alzinova AB
- Website
- https://alzinova.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Alzinova industry classification
Industry- Product category
- Alzheimer's Disease Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Alzinova is headquartered
LocationHeadquarters
- HQ city
- Gothenburg
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Alzinova business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pre-commercial / Product Revenue (Future): Alzinova is a clinical-stage biopharma company with no current commercial products or revenue. The company is developing ALZ-101 (vaccine in Phase 1b) and ALZ-201 (monoclonal antibody in preclinical development) for Alzheimer's disease treatment. Future revenue will come from product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Alzinova product offering
Product offeringCore offering
Alzinova fundamentally develops disease-modifying immunotherapies targeting toxic amyloid-β oligomers in Alzheimer's disease. Its lead candidate, ALZ-101, is an oligomer-specific therapeutic vaccine that stimulates patients' immune systems to produce antibodies against toxic oligomers, currently in Phase 1b clinical trials. Its second candidate, ALZ-201, is an oligomer-specific monoclonal antibody in preclinical development, intended for stand-alone or combination therapy. Both candidates are built on the proprietary AβCC Peptide™ Technology platform that enables specific oligomer targeting with unprecedented discrimination from monomers and fibrils.
Product overview
Alzinova is a Swedish clinical-stage biopharma company pioneering the development of disease-modifying treatments against Alzheimer's disease. The company operates a portfolio-based approach with two main programs: ALZ-101 (therapeutic vaccine in Phase 1b clinical trials) and ALZ-201 (monoclonal antibody in preclinical development). Both products are generated from the proprietary AβCC Peptide™ Technology platform, which enables specific targeting of toxic amyloid-beta oligomers. The company is headquartered in Mölndal, Sweden, with shares listed on Nasdaq First North Growth Market.
Differentiator
Problem solved
Functional benefit
Products and services
- ALZ-101 ALZ-101 is an oligomer-specific therapeutic vaccine designed to stimulate the patient's immune system to produce antibodies against toxic amyloid-β oligomers for the treatment of Alzheimer's disease. The vaccine completed Phase 1b clinical trials demonstrating a 95%+ immune responder rate over an 84-week study, good tolerability, acceptable safety profile, and antibodies reaching the central nervous system. It is being prepared for Phase 2 clinical studies.
- ALZ-201 ALZ-201 is an oligomer-specific humanized monoclonal antibody (originally murine IgG isotype) with extremely high oligomer specificity that does not react with functional (non-aggregated) or inert (fibrillar) amyloid-β and does not cross-react with Aβ40. It is intended for use as a stand-alone disease-modifying therapy or as a complement to the ALZ-101 vaccine, and is currently in preclinical development with humanization completed.
Quantifiable outcome
- 95%+ immune response rate (31 of 32 patients generated desired immune response)
- +2 more outcomes
Companies that use Alzinova
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Alzinova technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alzinova partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- FujirebiocoreLetter of Intent signed regarding potential commercialization of blood-based Alzheimer's diagnostic test. This partnership could enable broader patient access to diagnostic capabilities supporting ALZ-101 treatment. Alzinova CEO Tord Labuda discussed the partnership in the context of precision vaccines and diagnostics integration.
- Ernst & Young ABcoreThe company's auditor is Ernst & Young AB, Gothenburg. Linda Sallander is the auditor in charge and partner at EY with many years of experience in leading audit engagements for listed companies and Life Science sector. Member of FAR, the association of Swedish professional accountants.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Alzinova competitors and assessment
Company assessmentDirect peers
- BioArctic AB: Swedish clinical-stage biotech developing immunotherapies and antibodies for Alzheimer's disease, including the lecanemab antibody (marketed as LEQEMBI by Eisai/Biogen). Most directly comparable peer given shared Swedish origin, AD focus, and antibody/immunotherapy approach.
- AC Immune SA: Swiss clinical-stage biotech developing both active immunotherapy vaccines (ACI-35) and passive antibodies against Tau and Aβ for Alzheimer's disease. Highly comparable in therapeutic modality mix (vaccine + mAb) and target indication.
- Prothena Corporation: Ireland/US biotech developing monoclonal antibodies targeting misfolded proteins including amyloid-beta (PRX012) for Alzheimer's. Direct competitor in the anti-Aβ passive immunotherapy space with similar scientific approach.
- Cognition Therapeutics: US clinical-stage biotech focused on small-molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. Comparable as a small-cap AD-focused company navigating similar clinical development and partnership pathways.
Broad incumbents
- Eisai Co., Ltd. Japanese Big Pharma with the leading FDA-approved anti-amyloid antibody LEQEMBI (lecanemab). Major incumbent in the AD space and a potential partner/acquirer for Alzinova given active Big Pharma discussions.
- Biogen Inc. US Big Pharma with the leading AD franchise (aducanumab withdrawn, LEQEMBI co-commercialized with Eisai). Co-promoter of LEQEMBI and major incumbent competitor; potential partner for Alzinova's oligomer-specific approach.
Emerging players
- Cassava Sciences: US clinical-stage biotech developing simufilam for Alzheimer's disease. Similar profile as a small-cap, single-indication-focused AD biotech navigating late-stage clinical development and partnership dynamics.
- Anavex Life Sciences: US clinical-stage biotech developing ANAVEX compounds (e.g., blarcamesine) for Alzheimer's and Rett syndrome. Comparable as a small-cap neurodegenerative-disease biotech with limited near-term revenue.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Alzinova social profiles
Digital presenceAlzinova financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alzinova leadership team
Management profileNumber of profiles
Profiles11 records
Alzinova funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alzinova M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alzinova
What does Alzinova do?
Alzinova fundamentally develops disease-modifying immunotherapies targeting toxic amyloid-β oligomers in Alzheimer's disease. Its lead candidate, ALZ-101, is an oligomer-specific therapeutic vaccine that stimulates patients' immune systems to produce antibodies against toxic oligomers, currently in Phase 1b clinical trials. Its second candidate, ALZ-201, is an oligomer-specific monoclonal antibody in preclinical development, intended for stand-alone or combination therapy. Both candidates are built on the proprietary AβCC Peptide™ Technology platform that enables specific oligomer targeting with unprecedented discrimination from monomers and fibrils.
Is Alzinova a public or private company?
Alzinova is a public company. It is classified as public and is currently operating.
When was Alzinova founded?
Alzinova was founded in 2011. It employs 1 to 10 people.
Where is Alzinova based?
Alzinova is headquartered in Gothenburg, Sweden, in the Europe region.
How does Alzinova make money?
One revenue line is on record: pre-commercial / Product Revenue (Future).
Who are Alzinova's main competitors?
Direct peers on record are BioArctic AB, AC Immune SA, Prothena Corporation and Cognition Therapeutics. Broad incumbents are Eisai Co., Ltd. and Biogen Inc.. Emerging players are Cassava Sciences and Anavex Life Sciences.
Does Alzinova have an API?
No public API is recorded for Alzinova.
What industry is Alzinova in?
Alzinova's product category is Alzheimer's Disease Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2836.